<DOC>
	<DOCNO>NCT00512291</DOCNO>
	<brief_summary>The objective study determine tolerability safety olanzapine administer subcutaneous injection hospitalize patient hyperactive mixed delirium .</brief_summary>
	<brief_title>Subcutaneous Olanzapine Hyperactive Mixed Delirium</brief_title>
	<detailed_description>Olanzapine drug design control agitation/delirium . Olanzapine give mouth injection muscle , painful increase person 's feeling agitation . In study , olanzapine give skin catheter . Researchers hope less painful agitate injected muscle . If find eligible take part study , catheter ( plastic tube ) place skin . This catheter use give study medication . Study drug give catheter every 8 hour 9 dos . Each shot take 1 2 minute . You receive drug M.D.Anderson Cancer Center . Researchers use Richmond Agitation Scale measure agitation sedation injection olanzapine catheter . It take 5 10 minute answer question . You evaluate catheter site reaction time injection , 30 minute 1 hour injection , injection study drug . Your blood pressure evaluate 1 hour first two injection day study . If agitation control , receive haloperidol . On second day treatment , researcher record amount haloperidol use previous 24 hour . If amount haloperidol use great certain amount , dose olanzapine increase . Even dose olanzapine increase , may still able use haloperidol need . On third day treatment , researcher record amount haloperidol use previous 24 hour . If amount haloperidol use great certain amount , dose olanzapine increase . As , dose olanzapine increase , may still able use haloperidol need . If respond olanzapine 3 day treatment , give option continue drug off-study . If develop severe side effect complete 9 dos , treatment stop . If treatment study stop , consult doctor receive different medication study help control symptom . There long-term follow-up study . This investigational study . Olanzapine FDA approve give muscle mouth treatment agitation relate schizophrenia bipolar mania ( disorder involve mood swing deep depression feeling elation ) . A total 25 patient take part study . All enrol M.D . Anderson .</detailed_description>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Hospitalized patient Acute Palliative Care Unit ( G12NW ) University Texas MD Anderson Cancer Center 2 . Age &gt; 18 year age ( Olanzapine IM evaluate pediatric patient . ) 3 . Patients must acceptable surrogate capable give consent subject 's behalf . 4 . Richmond AgitationSedation Score ( RASS ) &gt; /= 1 5 . Mini Mental Status Exam score less 24 6 . Hyperactive mixed delirium responsive least 10 mg haloperidol within last 24 hour 1 . Known hypersensitivity ingredient olanzapine IM 2 . The following reaction haloperidol : A ) Acute dystonia B ) Hypersensitivity previous intolerance haloperidol C ) Extra pyramidal side effect 3 . History narrowangle glaucoma . 4 . Systolic blood pressure &lt; 90 mm Hg 5 . If receive injectable depot neuroleptic within less one dosing interval study initiation 6 . Within 7 day start study drug , documentation : a. Fasting blood glucose ( finger stick glucose check ) &gt; 250 mg/dl b . Absolute neutrophil count &lt; 500 platelet &lt; 50,000 7 . The use benzodiazepines neuroleptic medication , besides haloperidol , patient enrol study , prohibit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Hyperactive Delirium</keyword>
	<keyword>Mixed Delirium</keyword>
	<keyword>Olanzapine</keyword>
</DOC>